Drugs / Qingzhu Granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06068478 | Nov 2023 → Apr 2025 | gout | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qingzhu Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06068478 ↗ |
| Route | Oral | “Oral administration” NCT06068478 ↗ |